<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00976976</url>
  </required_header>
  <id_info>
    <org_study_id>AMC0604</org_study_id>
    <nct_id>NCT00976976</nct_id>
  </id_info>
  <brief_title>Adjuvant Chemotherapy With Docetaxel, Capecitabine and Cisplatin in Patients With Advanced Gastric Cancer: Adjuvant DXP</brief_title>
  <official_title>Phase 2 Study of Adjuvant Chemotherapy With Docetaxel, Capecitabine and Cisplatin in Patients With Advanced Gastric Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Asan Medical Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Asan Medical Center</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Despite the improvement of surgical resection as primary curative treatment for gastric&#xD;
      cancer, more than 70% of patients with stage IIIB and IV disease undergoing radical primary&#xD;
      tumor resection relapse and die within 5 years. Therefore, there is an urgent need to further&#xD;
      improve the treatment for gastric cancer in this population. Recently reported phase III&#xD;
      study comparing capecitabine/cisplatin (XP) versus 5-FU/cisplatin (FP), XP showed better&#xD;
      activity and tolerability compared with FP. To improve treatment outcomes of XP chemotherapy,&#xD;
      the investigators performed a phase I-II study of docetaxel, capecitabine and cisplatin in&#xD;
      advanced gastric cancer (AGC). Phase I-II study of docetaxel, capecitabine and cisplatin as&#xD;
      first-line chemotherapy in advanced gastric cancer (Kang et al, Proc Am Soc Clin Oncol&#xD;
      22,328.2003). The docetaxel/capecitabine/cisplatin (DXP) chemotherapy was highly active for&#xD;
      the 1st-line chemotherapy of AGC. These findings and experience encourages the investigators&#xD;
      to design the adjuvant trial of DXP chemotherapy in patients with resected gastric cancer.&#xD;
      The aim of this study is to assess the efficacy and safety of adjuvant DXP in this patient&#xD;
      population.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Previous in phase II study of docetaxel, capecitabine and cisplatin,total 40 pts with&#xD;
      measurable disease, median 6 cycles of chemotherapy, there were 4 confirmed complete&#xD;
      responses (CRs) and 23 confirmed partial responses (PRs), with the overall response rate of&#xD;
      67.5% (95% confidence interval, 52.7 ~ 82.3) in intention-to-treat analysis. Ten patients&#xD;
      underwent surgical resection after 4 ~ 9 cycles of chemotherapy. Four pathologic CRs were&#xD;
      identified. With a median follow-up of 14 months (range, 1 to 28), median time to progression&#xD;
      was 7.7 months, and median overall survival was 16.9 months. The DXP chemotherapy was highly&#xD;
      active for the 1st-line chemotherapy of AGC (Kang et al, Proc Am Soc Clin Oncol 22,328.2003).&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>May 2007</start_date>
  <completion_date type="Actual">September 2011</completion_date>
  <primary_completion_date type="Actual">September 2011</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>This protocol will evaluate the possible benefit of adjuvant docetaxel, capecitabine, and cisplatin combination chemotherapy in patients with resected gastric cancer pathologic stage IIIB and IV in terms of relapse free survival.</measure>
    <time_frame>5 years</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Investigate the safety profiles, patient tolerance, and overall survival in this population</measure>
    <time_frame>5 years</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">46</enrollment>
  <condition>Resected Advanced Gastric Cancer</condition>
  <arm_group>
    <arm_group_label>DXP</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>docetaxel, capecitabine, cisplatin</intervention_name>
    <description>Docetaxel 60 mg/m2 IV (day 1) every 21 days capecitabine 1,875 mg/m2/day PO, divided two (day 1-day14) every 21 days Cisplatin 60 mg/m2 IV (day 1) every 21 days</description>
    <arm_group_label>DXP</arm_group_label>
    <other_name>docetaxel,xeloda,cisplatin</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Histologically or cytologically documented gastric adenocarcinoma&#xD;
&#xD;
          -  Age 18 -70&#xD;
&#xD;
          -  Eastern Cooperative Oncology Group (ECOG) performance status 0-1&#xD;
&#xD;
          -  Pathologic stage IIIB or IV&#xD;
&#xD;
          -  complete resection (R0 resection)&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Other tumor type than adenocarcinoma&#xD;
&#xD;
          -  R1 or R2 resection&#xD;
&#xD;
          -  Presence of distant metastasis&#xD;
&#xD;
          -  Gastric outlet obstruction or intestinal obstruction&#xD;
&#xD;
          -  Evidence of gastrointestinal bleeding&#xD;
&#xD;
          -  Other serious illness or medical conditions&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Yoon-Koo Kang, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Asan Medical Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Asan Medical Center</name>
      <address>
        <city>Seoul</city>
        <state>Songpa-gu</state>
        <zip>138-736</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>January 2020</verification_date>
  <study_first_submitted>September 14, 2009</study_first_submitted>
  <study_first_submitted_qc>September 14, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 15, 2009</study_first_posted>
  <last_update_submitted>January 6, 2020</last_update_submitted>
  <last_update_submitted_qc>January 6, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">January 7, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Asan Medical Center</investigator_affiliation>
    <investigator_full_name>Yoon-Koo Kang</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <keyword>Resected advanced gastric cancer stage IIIB and IV</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Stomach Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cisplatin</mesh_term>
    <mesh_term>Docetaxel</mesh_term>
    <mesh_term>Capecitabine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

